Table 3.
Summary of AEs (safety analysis set).
| Atezolizumab + bevacizumab | |
|---|---|
| N = 43 | |
| Any AE | 41 (95.3) |
| Grade ≥3 AE | 11 (25.6) |
| AE leading to treatment interruption | 7 (16.3) |
| AE leading to treatment discontinuation | 2 (4.7) |
| AE leading to death | 1 (2.3) |
| Atezolizumab-related AE | 39 (90.7) |
| Atezolizumab-related serious AE | 7 (16.3) |
| Bevacizumab-related AE | 38 (88.4) |
| Bevacizumab-related serious AE | 7 (16.3) |
Note: Data are n (%).